Fatty liver medical therapy

Jump to navigation Jump to search

Fatty Liver Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Fatty Liver from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Fatty liver medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Fatty liver medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Fatty liver medical therapy

CDC on Fatty liver medical therapy

Fatty liver medical therapy in the news

Blogs on Fatty liver medical therapy

Directions to Hospitals Treating Fatty liver

Risk calculators and risk factors for Fatty liver medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

The treatment of fatty liver depends on what is causing it, and generally, treating the underlying cause will reverse the process of steatosis if implemented at early stage. Recent studies suggest that diet, exercise, and especially antiglycemic drugs may alter the course of the disease. A randomized controlled trial found that pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis.[1]

Elderly may not benefit from treatment[2].

Patients with nonalcoholic steatosis on imaging, but normal liver function tests, may not have increased risk and so not need treatment[3].

Medical Therapy

Clinical practice guidelines

Clinical practice guidelines direct treatment.

Per the American Gastroenterological Association (AGA) in 2021[4], per Figure 3 notes, treatment may include:

  • "Patients with T2DM may benefit from some diabetes medications, such as pioglitazone and some GLP-1 RAs that have reported histological improvement in RCTs in patients with NASH, either with or without diabetes. Among GLP-1 RAs, semaglutide has the strongest evidence of liver histological benefit."
  • "Vitamin E improves steatohepatitis in patients with NASH without diabetes, with less evidence in patients with T2D."

Per the American Association for the Study of Liver Diseases (AASLD) in 2023[5]:

  • "Semaglutide can be considered for its approved indications (T2DM/obesity) in patients with NASH, as it confers a cardiovascular benefit and improves NASH."
  • "Pioglitazone improves NASH and can be considered for patients with NASH in the context of patients with T2DM."
  • "Vitamin E can be considered in select individuals as it improves NASH in some patients without diabetes."

"Available data on semaglutide, pioglitazone, and vitamin E do not demonstrate an antifibrotic benefit, and none has been carefully studied in patients with cirrhosis."

Systematic reviews

Systematic reviews are available, including a network meta-analysis (NMA)[6].

Original studies

Key trials include:

References

  1. 1.0 1.1 Belfort R, Harrison SA, Brown K; et al. (2006). "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis". N. Engl. J. Med. 355 (22): 2297–307. doi:10.1056/NEJMoa060326. PMID 17135584.
  2. van Kleef LA, Sonneveld MJ, Kavousi M, Ikram MA, de Man RA, de Knegt RJ (2022). "Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study". Hepatology. doi:10.1002/hep.32635. PMID 35753042 Check |pmid= value (help).
  3. Natarajan Y, Kramer JR, Yu X, Li L, Thrift AP, El-Serag HB; et al. (2020). "Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes". Hepatology. 72 (4): 1242–1252. doi:10.1002/hep.31157. PMC 8318072 Check |pmc= value (help). PMID 32022277 Check |pmid= value (help).
  4. Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E; et al. (2021). "Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease". Gastroenterology. 161 (5): 1657–1669. doi:10.1053/j.gastro.2021.07.049. PMC 8819923 Check |pmc= value (help). PMID 34602251 Check |pmid= value (help).
  5. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D; et al. (2023). "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease". Hepatology. doi:10.1097/HEP.0000000000000323. PMID 36727674 Check |pmid= value (help).
  6. Majzoub AM, Nayfeh T, Barnard A, Munaganuru N, Dave S, Singh S; et al. (2021). "Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH". Aliment Pharmacol Ther. 54 (7): 880–889. doi:10.1111/apt.16583. PMC 8711247 Check |pmc= value (help). PMID 34435378 Check |pmid= value (help).
  7. Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V; et al. (2021). "A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis". N Engl J Med. 384 (12): 1113–1124. doi:10.1056/NEJMoa2028395. PMID 33185364 Check |pmid= value (help).
  8. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM; et al. (2010). "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis". N Engl J Med. 362 (18): 1675–85. doi:10.1056/NEJMoa0907929. PMC 2928471. PMID 20427778. Review in: Ann Intern Med. 2010 Sep 21;153(6):JC3-12
  9. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF; et al. (2015). "Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial". Lancet. 385 (9972): 956–65. doi:10.1016/S0140-6736(14)61933-4. PMC 4447192. PMID 25468160.
  10. HIGHLIGHTS OF PRESCRIBING INFORMATION. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207999s003lbl.pdf
  11. Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ; et al. (2021). "A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH". N Engl J Med. 385 (17): 1547–1558. doi:10.1056/NEJMoa2036205. PMID 34670042 Check |pmid= value (help).
  12. Sanyal A, Charles ED, Neuschwander-Tetri BA, Loomba R, Harrison SA, Abdelmalek MF; et al. (2019). "Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial". Lancet. 392 (10165): 2705–2717. doi:10.1016/S0140-6736(18)31785-9. PMID 30554783.

Template:WS Template:WH